How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,875 results for

Uric Acid

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Relationship between serum uric acid and clustering of cardiovascular disease risk factors and renal disorders among Shanghai population: a multicentre and cross-sectional study. Full Text available with Trip Pro

Relationship between serum uric acid and clustering of cardiovascular disease risk factors and renal disorders among Shanghai population: a multicentre and cross-sectional study. To estimate the current prevalence of cardiovascular disease risk factors (CRFs) and renal disorders across serum uric acid (SUA) quartiles, and evaluate the relationships between SUA and CRFs and renal diseases in Shanghai population.Observational, cross-sectional study.Data were obtained from the physical check-up

2019 BMJ open

82. Precipitation of Soluble Uric Acid is Necessary for in vitro Activation of the NLRP3 Inflammasome in Primary Human Monocytes. Full Text available with Trip Pro

Precipitation of Soluble Uric Acid is Necessary for in vitro Activation of the NLRP3 Inflammasome in Primary Human Monocytes. To investigate the effects of soluble uric acid (UA) on expression and activation of the NODlike receptor (NLR) pyrin domain containing protein 3 (NLRP3) inflammasome in human monocytes to elucidate the role of hyperuricemia in the pathogenesis of gout.Primary human monocytes and the THP-1 human monocyte cell line were used to determine the effects of short- and long

2019 Journal of Rheumatology

83. Association between smoking and serum uric acid in Korean population: Data from the seventh Korea national health and nutrition examination survey 2016. Full Text available with Trip Pro

Association between smoking and serum uric acid in Korean population: Data from the seventh Korea national health and nutrition examination survey 2016. The aim of this study was to identify any association between serum uric acid and smoking status using data from the Seventh Korea National Health and Nutrition Examination Survey (KNHANES VII-1) 2016 of the Korean population.This study used a cross-sectional design and analyzed 5609 subjects aged ≥ 19 years among 8150 participants enrolled (...) in the KNHANES VII-1 2016. Smoking status was classified into current smokers, never smokers, and ex-smokers. Hyperuricemia was defined as > 7.0 mg/dL for men and > 6.0 mg/dL of serum uric acid for women. Association between smoking and serum uric acid/hyperuricemia was assessed by Pearson's or Spearman's correlation analyses and multivariate logistic regression analysis showing odds ratio (OR) and 95% confidence interval (CI).A significant difference in serum uric acid according to smoking status

2019 Medicine

84. The Association Between Uric Acid, Renal Hemodynamics and Arterial Stiffness Over the Natural History of Type 1 Diabetes. (Abstract)

The Association Between Uric Acid, Renal Hemodynamics and Arterial Stiffness Over the Natural History of Type 1 Diabetes. Higher plasma uric acid (PUA) concentrations are associated with renal vasoconstriction, renin angiotensin aldosterone system (RAAS) activation and vascular stiffness, however the timeline for these associations in type 1 diabetes (T1D) is not clear. We aimed to compare the changes in such associations over a wide range of T1D duration.PUA, glomerular filtration rate

2019 obesity & metabolism

85. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Full Text available with Trip Pro

Uric acid and the cardio-renal effects of SGLT2 inhibitors. Sodium/glucose co-transporter-2 (SGLT2) inhibitors, which lower blood glucose by increasing renal glucose elimination, have been shown to reduce the risk of adverse cardiovascular (CV) and renal events in type 2 diabetes. This has been ascribed, in part, to haemodynamic changes, body weight reduction and several possible effects on myocardial, endothelial and tubulo-glomerular functions, as well as to reduced glucotoxicity. This review (...) evaluates evidence that an effect of SGLT2 inhibitors to lower uric acid may also contribute to reduced cardio-renal risk. Chronically elevated circulating uric acid concentrations are associated with increased risk of hypertension, CV disease and chronic kidney disease (CKD). The extent to which uric acid contributes to these conditions, either as a cause or an aggravating factor, remains unclear, but interventions that reduce urate production or increase urate excretion in hyperuricaemic patients have

2019 obesity & metabolism

86. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. Full Text available with Trip Pro

Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. Objective To map the diverse health outcomes associated with serum uric acid (SUA) levels.Design Umbrella review.Data sources Medline, Embase, Cochrane Database of Systematic Reviews, and screening of citations and references.Eligibility criteria Systematic reviews and meta-analyses of observational studies that examined

2017 BMJ

87. WITHDRAWN: Α higher ratio of serum uric acid to serum creatinine could predict the risk of total and cause specific mortality - Insight from a US national survey. (Abstract)

WITHDRAWN: Α higher ratio of serum uric acid to serum creatinine could predict the risk of total and cause specific mortality - Insight from a US national survey. This article has been withdrawn at the request of the Publisher. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https: //www.elsevier.com/about/our-business/policies/article-withdrawal.Copyright © 2018. Published by Elsevier B.V.

2019 International journal of cardiology

88. Square wave voltammetric quantification of folic acid, uric acid and ascorbic acid in biological matrix Full Text available with Trip Pro

Square wave voltammetric quantification of folic acid, uric acid and ascorbic acid in biological matrix Nowadays, modified electrodes with metal nanoparticles have appeared as an alternative for the electroanalysis of various compounds. In this study, gold nanoparticles (GNPs) were chosen as interesting metal nanoparticles for modifying of carbon paste electrode (CPE). GNPs and the gold nanoparticles-modified carbon paste electrode (GNPs/CPE) were characterized by UV-Vis spectroscopy (...) , transmission electron microscopy (TEM) and scanning electron microscopy (SEM). GNPs/CPE as a simple and sensitive electrode was used to study three important biological molecules: folic acid (FA), uric acid (UA) and ascorbic acid (AA). Square wave voltammetry (SWV) was used as an accurate technique for quantitative measurements. A good linear relation was observed between anodic peak current (ipa) and FA (5.2 × 10-6 - 2.5 × 10-5 M), UA (1.2 × 10-6 - 2.1 × 10-5 M) and AA (1.2 × 10-6 - 2.5 × 10-5 M

2017 Journal of Pharmaceutical Analysis

89. Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: uric acid-lowering agents

Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: uric acid-lowering agents ____________________________________________________________________________________________________________ Early Chronic Kidney Disease December 2011 Page 1 of 9 Medical therapies to reduce chronic kidney disease progression and cardiovascular risk: uric acid-lowering agents Date written: July 2012 Author: Richard Phoon, David Johnson GUIDELINES a. We suggest that use of uric acid (...) be a consequence of reduced excretion, diuretic therapy, or oxidative stress. Although it is not clear whether urate plays a causative role or is an indirect marker of kidney function, uric acid lowering therapy has emerged as a potentially novel therapeutic treatment for slowing the progression of CKD[27] SEARCH STRATEGY ____________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 2 of 9 Databases searched: Text words

2013 KHA-CARI Guidelines

90. Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review. Full Text available with Trip Pro

Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review. Increasing evidence supports the association between hyperuricemia and incident chronic kidney disease (CKD); however, there are conflicting data regarding the role of hyperuricemia in the progression of CKD. This study retrospectively assessed the longitudinal association between uric acid (UA) level and CKD progression in a Chinese population lived in Taiwan.Patients with physician diagnosis (...) to renal failure increased 7% (hazard ratio 1.07, 95% CI 1.00, 1.14) for each 1mg/dL increase in baseline UA level. The influences of hyperuricemia on eGFR decline and the risk of kidney failure were more prominent in patients without proteinuria than those with proteinuria.Our study showed a higher uric acid level is associated with a significant rapid decline in eGFR and a higher risk of kidney failure, particularly in patients without proteinuria. Our findings suggest hyperuricemia is a potential

2017 PLoS ONE

91. Correction: Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease. Full Text available with Trip Pro

Correction: Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease. [This corrects the article DOI: 10.1371/journal.pone.0166290.].

2017 PLoS ONE

92. Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. (Abstract)

Serum uric acid and progression of diabetic nephropathy in type 1 diabetes. Uric acid (UA) is a risk factor for CKD. We evaluated UA in relation to change in GFR in patients with type 1 diabetes.Post hoc analysis of a trial of losartan in diabetic nephropathy, mean follow-up 3 years (IQR 1.5-3.5). UA was measured at baseline. Primary end-point was change in measured GFR. UA was tested in a linear regression model adjusted for known progression factors (gender, HbA1c, systolic blood pressure (...) (UAER, GFR, total cholesterol, HDL cholesterol) UA was associated with decline in GFR (r2 = 0.45, p < 0.001).Uric acid was weakly associated with decline in GFR in type 1 diabetic patients with overt nephropathy.Copyright © 2018. Published by Elsevier Inc.

2018 Journal of diabetes and its complications Controlled trial quality: uncertain

93. Impact of long-term potassium supplementation on thiazide diuretic-induced abnormalities of glucose and uric acid metabolisms. (Abstract)

Impact of long-term potassium supplementation on thiazide diuretic-induced abnormalities of glucose and uric acid metabolisms. Treatment of hypertension with thiazide diuretics may trigger hypokalemia, hyperglycemia, and hyperuricemia. Some studies suggest simultaneous potassium supplementation in hypertensive patients using thiazide diuretics. However, few clinical studies have reported the impact of long-term potassium supplementation on thiazide diuretic-induced abnormalities in blood (...) glucose and uric acid (UA) metabolisms. One hundred hypertensive patients meeting the inclusion criteria were equally randomized to two groups: IND group receiving indapamide (1.25-2.5 mg daily) alone, and IND/KCI group receiving IND (1.25-2.5 mg daily) plus potassium chloride (40 mmol daily), both for 24 weeks. At the end of 24-week follow-up, serum K+ level in IND group decreased from 4.27 ± 0.28 to 3.98 ± 0.46 mmol/L (P < 0.001), and fasting plasma glucose (FPG) and UA increased from 5.11 ± 0.52

2018 Journal of human hypertension Controlled trial quality: uncertain

94. Elevated serum uric acid affects myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. (Abstract)

Elevated serum uric acid affects myocardial reperfusion and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Elevated serum uric acid (eSUA) was associated with unfavorable outcome in patients with ST-segment elevation myocardial infarction (STEMI). However, the effect of eSUA on myocardial reperfusion injury and infarct size has been poorly investigated. Our aim was to correlate eSUA with infarct size, infarct size

2018 Journal of cardiovascular medicine (Hagerstown, Md.) Controlled trial quality: predicted high

95. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. (Abstract)

Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Gout is a painful disorder and is common in type 2 diabetes. Fenofibrate lowers uric acid and reduces gout attacks in small, short-term studies. Whether fenofibrate produces sustained reductions in uric acid and gout attacks is unknown.In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, participants aged 50-75 years with type 2 diabetes were (...) randomly assigned to receive either co-micronised fenofibrate 200 mg once per day or matching placebo for a median of 5 years follow-up. We did a post-hoc analysis of recorded on-study gout attacks and plasma uric acid concentrations according to treatment allocation. The outcomes of this analysis were change in uric acid concentrations and risk of on-study gout attacks. The FIELD study is registered with ISRCTN, number ISRCTN64783481.Between Feb 23, 1998, and Nov 3, 2000, 9795 patients were randomly

2018 The lancet. Diabetes & endocrinology Controlled trial quality: predicted high

96. Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). Full Text available with Trip Pro

Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). Hyperuricemia is supposed to be an independent risk factor for kidney dysfunction in diabetic patients. We attempted to examine the uric acid-lowering effect and the renoprotective effect of topiroxostat, a selective xanthine oxidoreductase (...) albumin-to-creatinine ratio in the first-morning-void urine sample. Secondary endpoints were changes in the estimated glomerular filtration rate and the serum uric acid level.At 28 weeks, there was no significant difference in the percent change from baseline in the urinary albumin-to-creatinine ratio between the two groups (topiroxostat: 0 vs. placebo: 17%, p = 0.3206), but the changes in the estimated glomerular filtration rate (- 0.2 vs. - 4.0 mL/min/1.73 m2, p = 0.0303) and the serum uric acid

2018 Clinical and experimental nephrology Controlled trial quality: predicted high

97. Acute effect of soy and soy products on serum uric acid concentration among healthy Chinese men. (Abstract)

Acute effect of soy and soy products on serum uric acid concentration among healthy Chinese men. Soy products are essential to the daily life of the Chinese population. However, the association between soy products and serum uric acid remains unclear. Better understanding of their relationship could provide food choice information for patients with gout. This study assessed the acute effects of soy and soy products on serum uric acid.Sixty healthy adult male volunteers were recruited (...) and randomly assigned to six groups. Ten participants in each group randomly ingested one of six foods: water, soy, and four different soy products. A blood test was conducted after 3 h to examine uric acid concentration.The serum uric acid concentration significantly increased by 21.4±23.4 μmol/L at 1 h and 16.3±19.4 μmol/L at 2 h following ingestion of whole soybeans. These changes also applied to the soy powder group. The serum uric acid concentration rapidly increased by 38.1±20.5 μmol/L at 1 h, 34.4

2018 Asia Pacific journal of clinical nutrition Controlled trial quality: uncertain

98. Uric Acid and Diabetic Nephropathy Risk. (Abstract)

Uric Acid and Diabetic Nephropathy Risk. Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) in the western world. Current treatment methods, with better control of glycemia and blood pressure, including renin-angiotensin system blockade (RASB), appear to have slowed the DN progression rate but have not substantially decreased the annual incidence of new DN ESRD cases. Thus, new treatment targets are needed.Higher levels of serum uric acid (UA) are associated

2018 Contributions to Nephrology

99. Continuous Positive Airway Pressure Treatment Does not Reduce Uric Acid Levels in OSA Women. (Abstract)

Continuous Positive Airway Pressure Treatment Does not Reduce Uric Acid Levels in OSA Women. Although an association between uric acid (UA) levels and obstructive sleep apnea (OSA) has been reported, the effect of continuous positive airway pressure (CPAP) on this measure is yet unclear. We aimed to investigate the effect of CPAP therapy on serum UA levels in patients with OSA.We conducted a multicenter, open-label, randomized controlled trial in 307 women diagnosed with moderate-to-severe OSA

2018 Archivos de bronconeumologia Controlled trial quality: uncertain

100. Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial. Full Text available with Trip Pro

Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial. Raised serum uric acid (SUA) level is commonly observed in patients with type 2 diabetes mellitus (T2DM) and is associated with increased morbidity and mortality. Sodium-glucose cotransporter 2 inhibitor, a novel oral diabetic drug, might exert a potential hypouricemic effect. We evaluated the effects of dapagliflozin on SUA levels (...) with baseline SUA levels (P<0.0001) but not correlated with changes in 24-hour urine volume, 24-hour urine glucose, or 24-hour urinary uric acid.Dapagliflozin could improve glycemic control and lower SUA levels in hospitalized patients with uncontrolled T2DM. Longer-time trials are required to further demonstrate the hypouricemic effect of dapagliflozin and explore the potential underlying mechanisms.

2018 Therapeutics and clinical risk management Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>